KAHR is developing novel bi-functional fusion proteins that convert cancer defense signals into selective offense beacons for the immune system to attack.
The company lead product, DSP107, is a CD47-41BB targeting compound that simultaneously target cancer cells, weaken their innate defenses and activate an effective, local response of both innate (by blocking ‘Don’t eat me’ signals) and adaptive immunity (by providing co-stimulation signal to T and NK cells).
The company recently announced a clinical collaboration agreement with Roche on a phase I/II which is planned to commence in the US during Q3/2020 to study DSP107 monotherapy and in combination with Atezolizumab for solid tumor patients.
1 Kiryat Hadassah JBP Bldg.
Jerusalem, Yerushalayim POB 9779
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Summer 2020 NYC Private Company Showcase
New York, NY,
August 10, 2020